List of Excipients in Branded Drug NEXIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	NEXIUM	esomeprazole magnesium	0186-5020	ALCOHOL
AstraZeneca Pharmaceuticals LP	NEXIUM	esomeprazole magnesium	0186-5020	BUTYL ALCOHOL
AstraZeneca Pharmaceuticals LP	NEXIUM	esomeprazole magnesium	0186-5020	D&C RED NO. 28

NEXIUM Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 3, 2026

NEXIUM is the branded product for esomeprazole, a proton-pump inhibitor available in delayed-release capsules, oral granules, intravenous products, and over-the-counter 24-hour treatment. Its commercial value depends on formulation control rather than active-ingredient exclusivity. The principal technical barrier is protecting esomeprazole from acid degradation while releasing it in the intestine.

The strongest commercial opportunities are generic delayed-release pellets, pediatric and dysphagia-friendly dosage forms, over-the-counter products, formulation-component supply, and manufacturing services. NEXIUM has no biosimilar exposure because esomeprazole is a chemically synthesized small molecule. Its original U.S. patent and regulatory exclusivity have expired, leaving formulation execution, manufacturing cost, brand recognition, and regulatory compliance as the main competitive factors.

What is NEXIUM and which formulations use excipient protection?

NEXIUM contains esomeprazole, the S-isomer of omeprazole. Esomeprazole magnesium is used in oral products, while esomeprazole sodium is used in the intravenous formulation.

The oral dosage forms use delayed-release technology. The product is not protected by a simple gelatin capsule. The capsule contains enteric-coated drug pellets designed to resist gastric acid and release esomeprazole at a higher intestinal pH.

Product format	Active ingredient	Primary formulation objective	Key excipient function
Delayed-release capsule	Esomeprazole magnesium	Intestinal release	Sugar spheres, polymeric seal and enteric coats, lubricants, capsule shell
Oral suspension granules	Esomeprazole magnesium	Administration to patients unable to swallow capsules	Granule protection, suspension performance, palatability and dosing uniformity
NEXIUM 24HR OTC capsule	Esomeprazole magnesium equivalent to 20 mg esomeprazole	Once-daily nonprescription treatment	Enteric coating, capsule performance, moisture and stability control
Intravenous injection	Esomeprazole sodium	Parenteral delivery after reconstitution	pH control, chelation control, solution stability and reconstitution performance

The FDA-approved prescription label identifies excipient systems that include sucrose, hypromellose, magnesium stearate, crospovidone, talc, titanium dioxide, gelatin, and colorants, depending on strength and presentation.[1] The exact composition varies by product and dosage form.

How does the NEXIUM excipient strategy work?

The formulation strategy has four technical layers.

How do enteric polymers protect esomeprazole?

Esomeprazole is acid labile. The dosage form must prevent contact with gastric fluid until the pellets reach the small intestine. Manufacturers typically apply a polymeric enteric coat using materials such as methacrylic acid copolymers or related pH-dependent polymers.

The coating must achieve four results:

1. Maintain low release in acidic media.
2. Dissolve rapidly after exposure to intestinal pH.
3. Preserve drug content during storage.
4. Tolerate capsule filling, transport, and handling.

The enteric layer is normally applied over a seal coat. The seal coat separates the drug-containing pellet from the acidic or reactive components of the outer coating.

Why are sugar spheres used?

Sugar spheres provide a multiparticulate core for drug layering. They support uniform distribution of esomeprazole and create pellets that can receive several functional coatings. Multiparticulate systems also reduce dependence on the performance of a single large tablet matrix.

This architecture creates a practical generic barrier. A competitor must reproduce dissolution behavior, coating uniformity, stability, and dose delivery without necessarily copying the branded manufacturing process.

What is the role of hypromellose and coating excipients?

Hypromellose can act as a binder, film former, or protective seal layer. Talc may support coating performance and reduce tack during fluid-bed processing. Triethyl citrate or comparable plasticizers can improve coating flexibility. Titanium dioxide and colorants support product identification and appearance.

These excipients are commercially important because variability in particle size, moisture, viscosity, surface area, and residual solvents can affect coating quality and dissolution.

Why does magnesium matter?

Esomeprazole magnesium is used to improve the pharmaceutical form of esomeprazole for oral delivery. The salt form affects crystallinity, hygroscopicity, dissolution, and stability. Suppliers and generic manufacturers must control the solid-state form and the relationship between the active pharmaceutical ingredient and the excipient matrix.

What patents protect NEXIUM?

NEXIUM's original exclusivity came from esomeprazole composition, formulation, manufacturing, and method-of-use rights, together with FDA regulatory exclusivity. Those protections have expired in the United States.

AstraZeneca's patent portfolio included U.S. patents covering esomeprazole and pharmaceutical formulations. Public patent records identify U.S. Patent No. 5,714,504, which covered esomeprazole-related subject matter and had an expiration date in the mid-2010s, subject to patent-term adjustment and other statutory calculations.[2] Other formulation and method patents extended portions of the estate, but the principal U.S. market exclusivity period ended before the current generic market matured.

The relevant commercial point is that NEXIUM is no longer protected by a live core patent that prevents ordinary generic entry in the United States. Remaining rights may exist in specific jurisdictions, manufacturing processes, combinations, or later-developed products, but they do not recreate the original branded monopoly.

When did NEXIUM lose exclusivity?

NEXIUM lost effective U.S. market exclusivity in stages.

Event	Approximate timing	Commercial effect
Original esomeprazole patent protection	Mid-2010s	Core composition and formulation protection began to expire
Authorized and independent generic activity	2010s	Price competition increased
NEXIUM 24HR OTC launch	2015	Brand shifted part of its value to consumer distribution
OTC generic competition	2010s onward	Shelf-space, packaging and retail economics became more important
Current market	2020s	Multiple generic and branded-equivalent suppliers compete

The exact launch date for a particular generic depends on FDA approval, Paragraph IV litigation, settlement terms, supply readiness, and dosage form. FDA's Orange Book remains the operative source for listed patents and regulatory exclusivity for approved prescription products.[3]

What is the Orange Book status of NEXIUM?

The Orange Book historically listed NEXIUM delayed-release capsules, oral suspension, and injection products under AstraZeneca entities and related product sponsors. The key branded patents and regulatory exclusivities associated with the original NEXIUM franchise have expired.

For business planning, Orange Book analysis should distinguish:

• Prescription NEXIUM products.
• NEXIUM 24HR OTC products, which are not governed by the prescription Orange Book in the same manner.
• Authorized generics.
• Generic abbreviated new drug applications for delayed-release capsules and suspension.
• Patents listed against particular dosage strengths or presentations.

A live Orange Book listing does not automatically prevent approval. A generic applicant can certify to the patent, wait for expiration, or challenge the listing through a Paragraph IV certification.

Which companies challenged NEXIUM patents?

NEXIUM faced generic competition from major U.S. and international manufacturers, including Teva, Mylan, Dr. Reddy's Laboratories, and other ANDA sponsors. AstraZeneca brought patent litigation against generic applicants during the period when relevant patents remained enforceable.

Paragraph IV challenges generally asserted that listed patents were invalid, unenforceable, or not infringed. Patent settlements and launch arrangements varied by defendant and product. The commercial impact was significant because each early generic entrant could reduce capsule pricing and shift pharmacy substitution away from the branded product.

The main litigation risk is now historical for the original prescription franchise. Current disputes are more likely to concern specific generic formulations, manufacturing processes, product quality, supply contracts, or later-developed delivery systems.

What formulations are protected by NEXIUM patents?

The commercially relevant formulation concepts include:

Delayed-release capsules

The capsule format protects a multiparticulate enteric-release system. Patent claims in this field may cover:

• Drug-loaded inert cores.
• Seal-coat compositions.
• Enteric polymer layers.
• Plasticizers and anti-tacking agents.
• Specific dissolution profiles.
• Stability under accelerated storage.
• Capsule filling and pellet-size distributions.

A generic manufacturer can design around a formulation patent by changing the pellet core, coating sequence, polymer, plasticizer, or manufacturing parameters, provided the final product satisfies FDA performance requirements.

Oral suspension and granules

Suspension products create separate IP opportunities because they must control:

• Reconstitution behavior.
• Particle dispersion.
• Dose uniformity.
• Palatability.
• In-use stability.
• Compatibility with administration devices.

Granules for pediatric use or patients with swallowing difficulty can command higher prices than standard capsules if they provide a meaningful administration advantage.

Intravenous products

The injectable product uses esomeprazole sodium and requires control of pH, reconstitution, solution clarity, particulate matter, and chemical stability. Excipient selection is narrower than in an oral multiparticulate product because each excipient must be suitable for parenteral administration.

How strong is the NEXIUM patent estate?

The original NEXIUM estate was commercially strong during the protected period but is now weak as a barrier to standard generic entry.

Estate component	Historical strength	Current commercial strength
Esomeprazole active ingredient	High	Low after expiration
Magnesium salt form	Moderate to high	Low for ordinary generic entry
Enteric-release pellets	High if narrowly claimed	Moderate for design-around risk
Specific excipient combinations	Moderate	Product-specific
Pediatric suspension	Moderate to high	Potentially valuable for differentiated products
Intravenous formulation	Moderate	Limited by established generic competition
Method-of-use claims	Useful for lifecycle management	Limited if expired or medically established
Brand, packaging and consumer recognition	High	Still relevant in OTC retail

The estate's residual value is concentrated in know-how: pellet processing, coating control, equipment settings, analytical methods, supplier qualification, and scale-up experience. Those assets are often more relevant to a new entrant than expired patent claims.

What generic entry risks exist for NEXIUM?

Generic entrants face five principal risks.

Bioequivalence and dissolution failure

The FDA expects delayed-release products to demonstrate appropriate pharmaceutical equivalence and bioequivalence. Dissolution must show acid resistance followed by release under intestinal conditions. Small changes in coating thickness or polymer grade can produce a failed profile.

Manufacturing variability

Fluid-bed coating is sensitive to spray rate, inlet temperature, atomization, bed temperature, and drying conditions. Scale-up can change pellet agglomeration, coating defects, and release timing.

Stability and moisture

Moisture can affect the active ingredient, enteric polymers, capsule shells, and pellet adhesion. Packaging may require high-barrier bottles, desiccants, or blister systems.

Excipient supply

A formulation can become commercially vulnerable if it depends on a single supplier for pharmaceutical-grade polymers, sugar spheres, colorants, or specialty grades of magnesium stearate.

Price compression

Esomeprazole is a mature generic market. Additional entrants may increase volume but reduce gross margin. The strongest economics are usually available through low-cost manufacturing, reliable supply, an OTC channel, or a differentiated dosage form.

What commercial opportunities exist in NEXIUM excipients?

Can excipient suppliers profit from NEXIUM generics?

Yes. The largest opportunities are in high-specification excipients and processing aids rather than commodity ingredients.

Potential suppliers include manufacturers of:

• Enteric polymers.
• Hypromellose grades.
• Plasticizers.
• Pharmaceutical talc.
• Sugar spheres.
• Moisture-control packaging.
• Capsule shells.
• Fluid-bed coating equipment.
• In-process dissolution testing systems.

A supplier with validated grades, regulatory documentation, global manufacturing, and consistent particle-size distribution can become embedded in a generic manufacturer's process.

Are co-processed excipients attractive?

Co-processed excipients may improve flow, compactibility, coating performance, or suspension behavior. Their value is higher when they reduce manufacturing steps or improve batch-to-batch reproducibility. The supplier must support regulatory filings with composition, manufacturing controls, impurity data, and change-control commitments.

Is there an opportunity for new NEXIUM dosage forms?

The most credible opportunities are:

• Orally disintegrating or sprinkle products.
• Pediatric granules.
• Lower-cost sachets.
• Unit-dose hospital packaging.
• Combination packs for short-term reflux treatment.
• Improved suspension systems.
• Low-moisture, high-stability capsules.
• Products designed for feeding-tube administration.

These products require more than a new excipient. They need evidence of dose uniformity, administration compatibility, stability, palatability, and bioequivalence or another appropriate regulatory pathway.

How does NEXIUM compare with other proton-pump inhibitors?

NEXIUM competes with omeprazole, lansoprazole, pantoprazole, and rabeprazole. Omeprazole is the closest technical comparator because esomeprazole is its S-isomer.

Product	Active ingredient	Common oral delivery strategy	Commercial position
NEXIUM	Esomeprazole	Enteric-coated pellets or granules	Strong historical brand and OTC recognition
Prilosec/generic omeprazole	Omeprazole	Enteric-coated multiparticulates or tablets	Broad, low-cost generic competition
Prevacid/generic lansoprazole	Lansoprazole	Delayed-release capsules, orally disintegrating products	Differentiated administration options
Protonix/generic pantoprazole	Pantoprazole	Delayed-release tablets and IV products	Strong hospital and prescription presence
AcipHex/generic rabeprazole	Rabeprazole	Delayed-release tablets	Smaller branded and generic segment

NEXIUM's excipient opportunity is therefore not based on therapeutic exclusivity. It depends on manufacturing cost, dosage-form convenience, channel access, and product quality.

What is the FDA regulatory status of NEXIUM?

Prescription NEXIUM products were approved through the FDA new drug application pathway. Generic esomeprazole products are generally approved through ANDAs demonstrating pharmaceutical equivalence and bioequivalence to the relevant reference-listed drug.

NEXIUM 24HR is an OTC product for frequent heartburn treatment under the FDA's nonprescription framework. OTC competition places greater emphasis on labeling, packaging, consumer comprehension, tablet or capsule handling, and retail execution.[4]

There is no biosimilar pathway for NEXIUM. Biosimilars apply to biological products. Esomeprazole products are small-molecule drugs and compete through generic-drug and OTC pathways.

What licensing deals and manufacturing partnerships matter?

The most relevant commercial arrangements are usually formulation and supply agreements rather than licenses to the original NEXIUM patent estate. Potential deal structures include:

• Exclusive supply of enteric polymers.
• Dual-source agreements for critical excipients.
• Contract development and manufacturing of coated pellets.
• Technology transfer for fluid-bed coating.
• Regional commercialization rights for OTC products.
• Private-label supply for pharmacy and retail chains.
• Licensing of pediatric or sprinkle dosage forms.
• Packaging and serialization partnerships.

A buyer assessing such a deal should test freedom to operate, supplier-change obligations, process validation status, ANDA ownership, stability data, and the ability to qualify a second source without a regulatory supplement.

What revenue exposure does NEXIUM create?

NEXIUM generated multi-billion-dollar annual sales for AstraZeneca before generic erosion. Public company filings reported NEXIUM as one of AstraZeneca's major products during the peak branded period.[5] After loss of exclusivity, revenue migrated from the branded prescription product toward:

• Generic manufacturers.
• Authorized generics.
• OTC retail products.
• Private-label esomeprazole.
• Excipient and contract-manufacturing suppliers.
• Formulation products with administration advantages.

For investors, the relevant exposure is no longer branded NEXIUM revenue alone. It is the size of the global esomeprazole and proton-pump inhibitor market, the number of approved suppliers, pricing trends, channel mix, and manufacturing concentration.

What generic launch scenarios are most likely?

The standard scenario is continued price competition in delayed-release capsules. A differentiated entrant may target a smaller but higher-margin segment.

Launch scenario	Probability profile	Margin profile
Standard generic capsule	Common	Low to moderate
Authorized generic or private label	Common where supply is available	Low
Pediatric suspension or granules	Less crowded	Moderate to high
OTC retail product	Competitive but scalable	Moderate
Hospital IV product	Established competition	Low to moderate
Specialty sprinkle or feeding-tube product	Niche	Potentially high if clinically useful

Key Takeaways

• NEXIUM's core U.S. patent and exclusivity position has expired.
• The principal technical challenge is acid protection through enteric-coated multiparticulate delivery.
• Critical excipients include sugar spheres, hypromellose, enteric polymers, plasticizers, talc, lubricants, capsule materials, and parenteral stabilizing agents.
• Generic competition is driven by dissolution performance, coating consistency, stability, cost, and supply reliability.
• The strongest new-product opportunities are pediatric granules, sprinkle products, suspension systems, OTC formats, and hospital packaging.
• NEXIUM has no biosimilar risk because esomeprazole is a small molecule.
• Excipient suppliers can capture value through validated polymer grades, technical support, dual sourcing, and manufacturing-process integration.
• Current commercial risk is concentrated in price compression, supplier concentration, regulatory changes, and formulation-specific competition.

FAQs

Can a company patent a new NEXIUM excipient combination?

Yes. A new excipient combination may be patentable if it produces a non-obvious technical result, such as improved stability, dissolution, palatability, or dose uniformity. The claim must be distinguished from known esomeprazole and proton-pump inhibitor formulations.

Is esomeprazole magnesium more difficult to formulate than omeprazole?

It can be. The salt form, solid-state properties, moisture sensitivity, and acid-labile behavior affect processing and stability. The practical difficulty depends on the specific active form, pellet architecture, coating process, and packaging system.

Can a generic manufacturer use the same excipients as NEXIUM?

Generally, yes, if the manufacturer complies with applicable regulatory, quality, safety, and labeling requirements. Using the same excipients does not eliminate the need to establish product performance and bioequivalence.

Are NEXIUM oral granules commercially attractive?

They can be attractive where patients have swallowing limitations, need flexible administration, or require pediatric dosing. Their economics depend on manufacturing yield, packaging cost, palatability, stability, and the size of the target population.

Does NEXIUM still have meaningful patent litigation risk?

The original branded patent litigation risk is limited because the principal U.S. exclusivity period has ended. New disputes may arise from later formulation patents, manufacturing methods, product-specific ANDA issues, or commercial contracts.

References

1. U.S. Food and Drug Administration. (2023). NEXIUM (esomeprazole magnesium) delayed-release capsules and oral suspension: Prescribing information. AstraZeneca Pharmaceuticals LP.

2. United States Patent and Trademark Office. (1998). U.S. Patent No. 5,714,504: Esomeprazole compounds and pharmaceutical compositions. U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

4. U.S. Food and Drug Administration. (2015). NEXIUM 24HR (esomeprazole magnesium) delayed-release capsules: Drug facts labeling. https://www.accessdata.fda.gov

5. AstraZeneca PLC. (2015). Annual report and Form 20-F. AstraZeneca PLC.